Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2014 1
2018 1
2019 1
2020 3
2021 3
2022 2
2023 1
2024 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
International assessment of interobserver reproducibility of flap delineation in head and neck carcinoma.
Beddok A, Guzene L, Coutte A, Thomson D, Yom SS, Calugaru V, Blais E, Gilliot O, Racadot S, Pointreau Y, Corry J, Jensen K, Porceddu S, Khalladi N, Bastit V, Lasne-Cardon A, Marcy PY, Carsuzaa F, Nioche C, Bourhis J, Salleron J, Thariat J; GORTEC. Beddok A, et al. Acta Oncol. 2022 Jun;61(6):672-679. doi: 10.1080/0284186X.2022.2036367. Epub 2022 Feb 9. Acta Oncol. 2022. PMID: 35139735
Survival Without Quality of Life Deterioration in the GORTEC 2014-04 "OMET" Randomized Phase 2 Trial in Patients with Head and Neck Cancer with Oligometastases using Stereotactic Ablative Radiation Therapy (SABR) alone or Chemotherapy and SABR.
Thariat J, Bosset M, Falcoz A, Vernerey D, Pointreau Y, Racadot S, Faivre JC, Castelli J, Guihard S, Huguet F, Chapet S, Tao Y, Borel C, Fayette J, Rambeau A, Ferrand FR, Pechery A, Bourhis J, Sun XS; GORTEC, 4bis rue Emile Zola, Tours. Thariat J, et al. Int J Radiat Oncol Biol Phys. 2024 Nov 28:S0360-3016(24)03651-4. doi: 10.1016/j.ijrobp.2024.11.084. Online ahead of print. Int J Radiat Oncol Biol Phys. 2024. PMID: 39612953
Proton therapy for head and neck squamous cell carcinomas: A review of the physical and clinical challenges.
Beddok A, Vela A, Calugaru V, Tessonnier T, Kubes J, Dutheil P, Gerard A, Vidal M, Goudjil F, Florescu C, Kammerer E, Benezery K, Herault J, Poortmans P, Bourhis J, Thariat J; GORTEC, the 3 French proton centers. Beddok A, et al. Radiother Oncol. 2020 Jun;147:30-39. doi: 10.1016/j.radonc.2020.03.006. Epub 2020 Mar 27. Radiother Oncol. 2020. PMID: 32224315 Review.
[Otorhinolaryngology thematic issue. Presentation].
Vignot S, Thariat J; Étienne Bardet (GORTEC et coordinateur de l’intergroupe), Juliette Thariat (GORTEC), Dominique De Raucourt (GETTEC), Franck Jegoux (GETTEC), François Janot (GETTEC), Jean Lacau (GERCOR), Dominique Notelet (GERCOR), Benoist Chibaudel (GERCOR), Nadejda Vintonenko (manager Intergroupe), Jean Bourhis (GORTEC). Vignot S, et al. Bull Cancer. 2014 May;101(5):399. doi: 10.1684/bdc.2014.1961. Bull Cancer. 2014. PMID: 25814147 French. No abstract available.
Cetuximab versus methotrexate in first-line treatment of older, frail patients with inoperable recurrent or metastatic head and neck cancer (ELAN UNFIT): a randomised, open-label, phase 3 trial.
Guigay J, Ortholan C, Vansteene D, Cupissol D, Even C, Kaminsky MC, Sire C, Blot E, Debourdeau P, Bozec L, Saada-Bouzid E, Fayette J, Dalloz P, Pointreau Y, Caer HL, Falandry C, Digue L, Braccini A, Lopez S, Guillet P, Michel C, Cheurfa N, Schwob D, Bourhis J, Mertens C, Aupérin A; ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups and the GORTEC. Guigay J, et al. Lancet Healthy Longev. 2024 Mar;5(3):e182-e193. doi: 10.1016/S2666-7568(23)00284-2. Lancet Healthy Longev. 2024. PMID: 38432247 Free article. Clinical Trial.
[Proton therapy for head and neck squamous cell carcinomas: From physics to clinic].
Beddok A, Vela A, Calugaru V, Tessonnier T, Kubes J, Dutheil P, Gérard A, Vidal M, Goudjil F, Florescu C, Kammerer E, Bénézery K, Hérault J, Bourhis J, Thariat J; Gortec et de trois centres français. Beddok A, et al. Cancer Radiother. 2019 Sep;23(5):439-448. doi: 10.1016/j.canrad.2019.05.015. Epub 2019 Jul 26. Cancer Radiother. 2019. PMID: 31358445 Review. French.
Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: Results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02).
Racadot S, Thennevet I, Ouldbey Y, Kaminsky MC, Bosset M, Martin L, Tao Y, Sire C, de Raucourt D, Alfonsi M, Malaurie E, Tourani JM, Fournel P, Vauleon E, Modesto A, Rolland F, Metzger S, Pommier P, Chabaud S, Dussart S; GORTEC group. Racadot S, et al. Eur J Cancer. 2023 Jan;178:114-127. doi: 10.1016/j.ejca.2022.10.023. Epub 2022 Nov 9. Eur J Cancer. 2023. PMID: 36434888 Clinical Trial.
Adapted EXTREME regimen in the first-line treatment of fit, older patients with recurrent or metastatic head and neck squamous cell carcinoma (ELAN-FIT): a multicentre, single-arm, phase 2 trial.
Guigay J, Le Caer H, Ferrand FR, Geoffrois L, Saada-Bouzid E, Fayette J, Sire C, Cupissol D, Blot E, Guillet P, Pavillet J, Bozec L, Capitain O, Rolland F, Debourdeau P, Pointreau Y, Falandry C, Lopez S, Coutte A, Chatellier T, Dalloz P, Ortholan C, Michel C, Lacas B, Cheurfa N, Schwob D, Bourhis J, Mertens C, Aupérin A; ELAN Group including Gustave Roussy, Unicancer GERICO and H&N groups, and GORTEC. Guigay J, et al. Lancet Healthy Longev. 2024 Jun;5(6):e392-e405. doi: 10.1016/S2666-7568(24)00048-5. Epub 2024 May 14. Lancet Healthy Longev. 2024. PMID: 38759667 Free article. Clinical Trial.
15 results